Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma

Ankit Kansagra; Angela Dispenzieri; Raphael Fraser; Noel Estrada-Merly; Surbhi Sidana; Taiga Nishihori; Doris K. Hansen; Larry D. Anderson; Rahul Banerjee; Naresh Bumma; Binod Dhakal; Jack Khouri; Heather Landau; Cindy Lee; Hira Mian; Sunita Nathan; Bipin Savani; Shaji Kumar; Muzaffar Qazilbash; Nina Shah; Anita D'Souza

doi:10.1182/bloodadvances.2022007218

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma

Ankit Kansagra, Angela Dispenzieri, Raphael Fraser, Noel Estrada-Merly, Surbhi Sidana, Taiga Nishihori, Doris K. Hansen, Larry D. Anderson, Rahul Banerjee, Naresh Bumma, Binod Dhakal, Jack Khouri, Heather Landau, Cindy Lee, Hira Mian, Sunita Nathan, Bipin Savani, Shaji Kumar, Muzaffar Qazilbash, Nina ShahAnita D'Souza

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	3991-3995
Number of pages	5
Journal	Blood Advances
Volume	6
Issue number	13
DOIs	https://doi.org/10.1182/bloodadvances.2022007218
State	Published - Jul 12 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2022007218

Cite this

Kansagra, A., Dispenzieri, A., Fraser, R., Estrada-Merly, N., Sidana, S., Nishihori, T., Hansen, D. K., Anderson, L. D., Banerjee, R., Bumma, N., Dhakal, B., Khouri, J., Landau, H., Lee, C., Mian, H., Nathan, S., Savani, B., Kumar, S., Qazilbash, M., ... D'Souza, A. (2022). Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 6(13), 3991-3995. https://doi.org/10.1182/bloodadvances.2022007218

Kansagra, A, Dispenzieri, A, Fraser, R, Estrada-Merly, N, Sidana, S, Nishihori, T, Hansen, DK, Anderson, LD, Banerjee, R, Bumma, N, Dhakal, B, Khouri, J, Landau, H, Lee, C, Mian, H, Nathan, S, Savani, B, Kumar, S, Qazilbash, M, Shah, N & D'Souza, A 2022, 'Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma', Blood Advances, vol. 6, no. 13, pp. 3991-3995. https://doi.org/10.1182/bloodadvances.2022007218

@article{7660048978b74970b8fc8cdc94244a45,

title = "Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma",

author = "Ankit Kansagra and Angela Dispenzieri and Raphael Fraser and Noel Estrada-Merly and Surbhi Sidana and Taiga Nishihori and Hansen, {Doris K.} and Anderson, {Larry D.} and Rahul Banerjee and Naresh Bumma and Binod Dhakal and Jack Khouri and Heather Landau and Cindy Lee and Hira Mian and Sunita Nathan and Bipin Savani and Shaji Kumar and Muzaffar Qazilbash and Nina Shah and Anita D'Souza",

note = "Funding Information: Oncopeptides, Beigene, Antengene, and GLH Pharma. M.Q. reports research funding from Janssen, NeXimmune, Angiocrine, Bioline, and Amgen, participation on an advisory board from Onco-peptides, and participation on a data safety monitoring board with Autolus. A. D{\textquoteright}Souza reports research funding from Takeda, TeneoBio, Janssen, Sanofi, Regeneron, Prothena, and Caelum; board membership for BMS, Imbrium, Pfizer, and Prothena; and consultancy with Janssen. The remaining authors declare no competing financial interests. Funding Information: Conflict-of-interest disclosure: A.K. reports consulting fees from Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, and Takeda. S.S. reports research funding from Magenta Therapeutics, BMS, Allogene, and Janssen and consultancy with Magenta Therapeutics, BMS, Janssen, Sanofi, and Oncopeptides. T.N. reports clinical trial support to the institution from Novartis and clinical trial support (drug only supply) to the institution from Kayto-pharm. D.K.H. reports financial relationships within the past 12 months from OncLive (honoraria). L.D.A. reports financial relationships within the 36 months at UTSW with GSK (research grants), Janssen (research grants), BMS (research grants), Celgene (research grants), and Karyopharm (research grants); consulting fees and advisory board activity with GSK, Janssen, BMS, Celgene, Amgen, Oncopeptides, Karyopharm, and Prothena; and limits income to under 5K per company per year; DSMB: Prothena. R.B. reports financial relationships within the past 36 months with Sanofi (consulting), SparkCures (consulting), Guidepoint Global (consulting), Pack Health (institutional research funding), and University of California (employment). N.B. reports consultancy with Jansse and Sanofi and speaker bureau Amgen, Sanofi, and Oncopeptides. H.L. reports research support from Takeda; consulting fees from Pro-thena and Karyopharm; payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or education events from Sanofi/Genzyme; and participation on a data safety monitoring board or advisory board for BMS/Celgene, Janssen, Takeda, Caelum Biosciences, Karyopharm, Sanofi/Genzyme, and Pfizer. J.K. reports financial relationships within the past 36 months from OncLive (honoraria). B.D. reports financial relationships within the past 36 months with Celegene/BMS (honorarium), GSK (honorarium), and Karyopharm (honorarium) and has served as an advisory board member for Janssen, Arcellx, Natera, GSK, Amgen, and Takeda. C.L. reports advisory board membership with Janssen and BMS. H.M. reports having received research grant from Janssen and advisory board fees from BMS/Celgene, Takeda, Janssen, Amgen, GSK, and Sanofi. S.K. reports research funding for clinical trials to Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, and Molecular Templates; consulting/advisory board participation (with no personal payments) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeu-tics, Monterosa therapeutics, Trillium, and (with personal payment) Funding Information: Acknowledgments: The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service U24CA076518 from National Institutes of Health (NIH) National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Euro-fins Viracor; DBA Eurofins Transplant Diagnostics; Fate Therapeutics; Gamida-Cell, Ltd.; Gilead; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma Inc; Kite, a Gilead Company; Kyowa Kirin International plc; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Medac GmbH; Medexus,; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; OncoIm-mune, Inc.; Oncopeptides, Inc.; OptumHealth; Orca Biosystems, Inc.; Ossium Health, Inc; Pfizer, Inc.; Pharmacyclics, LLC; Prio-thera; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Talaris Therapeutics; Terumo Blood and Cell Technologies; TG Therapeutics; Tscan; Vertex; Vor Biopharma; and Xenikos BV.",

year = "2022",

month = jul,

day = "12",

doi = "10.1182/bloodadvances.2022007218",

language = "English (US)",

volume = "6",

pages = "3991--3995",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "13",

}

TY - JOUR

T1 - Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma

AU - Kansagra, Ankit

AU - Dispenzieri, Angela

AU - Fraser, Raphael

AU - Estrada-Merly, Noel

AU - Sidana, Surbhi

AU - Nishihori, Taiga

AU - Hansen, Doris K.

AU - Anderson, Larry D.

AU - Banerjee, Rahul

AU - Bumma, Naresh

AU - Dhakal, Binod

AU - Khouri, Jack

AU - Landau, Heather

AU - Lee, Cindy

AU - Mian, Hira

AU - Nathan, Sunita

AU - Savani, Bipin

AU - Kumar, Shaji

AU - Qazilbash, Muzaffar

AU - Shah, Nina

AU - D'Souza, Anita

N1 - Funding Information: Oncopeptides, Beigene, Antengene, and GLH Pharma. M.Q. reports research funding from Janssen, NeXimmune, Angiocrine, Bioline, and Amgen, participation on an advisory board from Onco-peptides, and participation on a data safety monitoring board with Autolus. A. D’Souza reports research funding from Takeda, TeneoBio, Janssen, Sanofi, Regeneron, Prothena, and Caelum; board membership for BMS, Imbrium, Pfizer, and Prothena; and consultancy with Janssen. The remaining authors declare no competing financial interests. Funding Information: Conflict-of-interest disclosure: A.K. reports consulting fees from Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, and Takeda. S.S. reports research funding from Magenta Therapeutics, BMS, Allogene, and Janssen and consultancy with Magenta Therapeutics, BMS, Janssen, Sanofi, and Oncopeptides. T.N. reports clinical trial support to the institution from Novartis and clinical trial support (drug only supply) to the institution from Kayto-pharm. D.K.H. reports financial relationships within the past 12 months from OncLive (honoraria). L.D.A. reports financial relationships within the 36 months at UTSW with GSK (research grants), Janssen (research grants), BMS (research grants), Celgene (research grants), and Karyopharm (research grants); consulting fees and advisory board activity with GSK, Janssen, BMS, Celgene, Amgen, Oncopeptides, Karyopharm, and Prothena; and limits income to under 5K per company per year; DSMB: Prothena. R.B. reports financial relationships within the past 36 months with Sanofi (consulting), SparkCures (consulting), Guidepoint Global (consulting), Pack Health (institutional research funding), and University of California (employment). N.B. reports consultancy with Jansse and Sanofi and speaker bureau Amgen, Sanofi, and Oncopeptides. H.L. reports research support from Takeda; consulting fees from Pro-thena and Karyopharm; payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or education events from Sanofi/Genzyme; and participation on a data safety monitoring board or advisory board for BMS/Celgene, Janssen, Takeda, Caelum Biosciences, Karyopharm, Sanofi/Genzyme, and Pfizer. J.K. reports financial relationships within the past 36 months from OncLive (honoraria). B.D. reports financial relationships within the past 36 months with Celegene/BMS (honorarium), GSK (honorarium), and Karyopharm (honorarium) and has served as an advisory board member for Janssen, Arcellx, Natera, GSK, Amgen, and Takeda. C.L. reports advisory board membership with Janssen and BMS. H.M. reports having received research grant from Janssen and advisory board fees from BMS/Celgene, Takeda, Janssen, Amgen, GSK, and Sanofi. S.K. reports research funding for clinical trials to Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, and Molecular Templates; consulting/advisory board participation (with no personal payments) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeu-tics, Monterosa therapeutics, Trillium, and (with personal payment) Funding Information: Acknowledgments: The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service U24CA076518 from National Institutes of Health (NIH) National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research. Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Euro-fins Viracor; DBA Eurofins Transplant Diagnostics; Fate Therapeutics; Gamida-Cell, Ltd.; Gilead; GlaxoSmithKline; HistoGenetics; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Kadmon; Karius; Karyopharm Therapeutics; Kiadis Pharma; Kite Pharma Inc; Kite, a Gilead Company; Kyowa Kirin International plc; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Medac GmbH; Medexus,; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; OncoIm-mune, Inc.; Oncopeptides, Inc.; OptumHealth; Orca Biosystems, Inc.; Ossium Health, Inc; Pfizer, Inc.; Pharmacyclics, LLC; Prio-thera; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Talaris Therapeutics; Terumo Blood and Cell Technologies; TG Therapeutics; Tscan; Vertex; Vor Biopharma; and Xenikos BV.

PY - 2022/7/12

Y1 - 2022/7/12

UR - http://www.scopus.com/inward/record.url?scp=85134538302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134538302&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2022007218

DO - 10.1182/bloodadvances.2022007218

M3 - Letter

C2 - 35507742

AN - SCOPUS:85134538302

SN - 2473-9529

VL - 6

SP - 3991

EP - 3995

JO - Blood Advances

JF - Blood Advances

IS - 13

ER -

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this